Calculator topics: Difference between revisions

Jump to navigation Jump to search
Line 13: Line 13:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Calculators
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Calculators
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Purpose
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Purpose
|-
! align="center" style="background:#DCDCDC;" + |Atrial fibrilation
| align="left" style="background:#F5F5F5;" + |[[HAS-BLED score]]
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |Atrial fibrilation
| align="left" style="background:#F5F5F5;" + |[[CHA2DS2-VASc Score]]
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |Atrial fibrilation
| align="left" style="background:#F5F5F5;" + |[[CHADS2 score]]
| align="left" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |[[TIMI Risk Score for STEMI]]
| align="left" style="background:#F5F5F5;" + |ACTION ICU Score for Intensive Care in NSTEMI
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts risk of NSTEMI complications requiring ICU care
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |[[TIMI Risk Score for Unstable Angina or NSTEMI]]
| align="left" style="background:#F5F5F5;" + |ADAPT Protocol for Cardiac Event Risk
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Assesses chest pain patients at 2 hours for risk of cardiac event
|-
! align="center" style="background:#DCDCDC;" + |DVT
| align="left" style="background:#F5F5F5;" + |[[AMUSE score calculator]]
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |DVT
| align="left" style="background:#F5F5F5;" + |[[HAMILTON score calculator]]
| align="left" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |DVT
! align="center" style="background:#DCDCDC;" + |DVT
| align="left" style="background:#F5F5F5;" + |[[Modified Wells score calculator for DVT]]
| align="left" style="background:#F5F5F5;" + |AMUSE score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Evaluates the need to proceed with ultrasonography among patients with suspected DVT
|-
|-
! align="center" style="background:#DCDCDC;" + |DVT
! align="center" style="background:#DCDCDC;" + |Anticoagulation
| align="left" style="background:#F5F5F5;" + |[[Wells score calculator for DVT]]
| align="left" style="background:#F5F5F5;" + |ATRIA Bleeding Risk Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Determines bleeding risk for patients on warfarin
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Arrythmia
| align="left" style="background:#F5F5F5;" + |[[Pulmonary embolism Wells score calculator]]
| align="left" style="background:#F5F5F5;" + |ATRIA Stroke Risk Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Determines stroke risk in patients with atrial fibrillation
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Arrythmia/Stroke
| align="left" style="background:#F5F5F5;" + |[[Pulmonary embolism modified Wells score calculator]]
| align="left" style="background:#F5F5F5;" + |Atrial Fibrillation Five Year Risk of Stroke (Framingham Heart Study)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 5-year risk of stroke in patients with atrial fibrillation
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Arrythmia/Stroke
| align="left" style="background:#F5F5F5;" + |[[Geneva score calculator]]
| align="left" style="background:#F5F5F5;" + |Atrial Fibrillation Five Year Risk of Stroke or Death (Framingham Heart Study)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 5-year risk of stroke or death in patients with atrial fibrillation
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Alcoholism
| align="left" style="background:#F5F5F5;" + |[[Simplified Geneva Score calculator]]
| align="left" style="background:#F5F5F5;" + |CAGE Questions for Alcohol Use
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Screens for excessive drinking and alcoholism
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Syncope
| align="left" style="background:#F5F5F5;" + |[[Revised Geneva score calculator]]
| align="left" style="background:#F5F5F5;" + |Canadian Syncope Risk Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 30-day serious adverse events in patients presenting with syncope
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |VTE
| align="left" style="background:#F5F5F5;" + |[[Caprini score calculator]]
| align="left" style="background:#F5F5F5;" + |Caprini score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Stratifies risk of VTE in surgical patients
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |[[IMPROVE risk score calculator]]
| align="left" style="background:#F5F5F5;" + |Cardiac Risk Index for AAA Surgery (Lee)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Calculates the approximate risk of cardiac complication after AAA surgery
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |[[IMPROVEDD risk score calculator]]
| align="left" style="background:#F5F5F5;" + |Cardiac Risk Index for Abdominal Surgery (Lee)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Calculates the approximate risk of cardiac complication after abdominal surgery
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |[[Padua prediction score]]
| align="left" style="background:#F5F5F5;" + |Cardiac Risk Index for Pre-Operative Risk, revised
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates risk of cardiac complications after noncardiac surgery
|-
|-
! align="center" style="background:#DCDCDC;" + |MACE
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |HEART Score for Major Cardiac  Events
| align="left" style="background:#F5F5F5;" + |Cardiovascular Risk Assessment (10-year, PROCAM Score, Munster Heart Study)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 10-year cardiovascular risk based on risk factors like history of MI, diabetes or high cholesterol
|-
|-
! align="center" style="background:#DCDCDC;" + |Blood pressure
! align="center" style="background:#DCDCDC;" + |Cardiac arrest
| align="left" style="background:#F5F5F5;" + |Mean Arterial Pressure (MAP)
| align="left" style="background:#F5F5F5;" + |CART (Cardiac Arrest Risk Triage) Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts risk of in-hospital cardiac arrest
|-
|-
! align="center" style="background:#DCDCDC;" + |ECG
! align="center" style="background:#DCDCDC;" + |Arrythmia/Stroke
| align="left" style="background:#F5F5F5;" + |Corrected QT Interval (QTc)
| align="left" style="background:#F5F5F5;" + |CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Calculates stroke risk for patients with atrial fibrillation, possibly better than the CHADS₂ Score
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Arrythmia/Stroke
| align="left" style="background:#F5F5F5;" + |PERC Rule for Pulmonary Embolism
| align="left" style="background:#F5F5F5;" + |CHADS₂ Score for Atrial Fibrillation Stroke Risk
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates stroke risk in patients with atrial fibrillation
|-
|-
! align="center" style="background:#DCDCDC;" + |Pre-operative risk
! align="center" style="background:#DCDCDC;" + |Survival
| align="left" style="background:#F5F5F5;" + |Revised Cardiac Risk Index for Pre-Operative Risk
| align="left" style="background:#F5F5F5;" + |Charlson Comorbidity Index (CCI)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 10-year survival in patients with multiple comorbidities
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Stroke
| align="left" style="background:#F5F5F5;" + |Bova score for pulmonary embolism complications
| align="left" style="background:#F5F5F5;" + |Cincinnati Prehospital Stroke Severity Scale (CP-SSS)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts large vessel occlusion (LVO) and severe stroke in patients with stroke symptoms
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |Coronary artery disease/Bleeding
| align="left" style="background:#F5F5F5;" + |Dash prediction score for recurrent vte
| align="left" style="background:#F5F5F5;" + |CRUSADE Score for Post-MI Bleeding Risk
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Stratifies bleeding risk after NSTEMI
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |VTE
| align="left" style="background:#F5F5F5;" + |Herdoo2 rule for discontinuing anticoagulation in unprovoked vte
| align="left" style="background:#F5F5F5;" + |DASH Prediction Score for Recurrent VTE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts likelihood of recurrence of first VTE
|-
|-
! align="center" style="background:#DCDCDC;" + |PE
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |Hestia criteria for outpatient pulmonary embolism treatment
| align="left" style="background:#F5F5F5;" + |Dual Antiplatelet Therapy (DAPT) Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts which patients will benefit from prolonged DAPT after coronary stent placement
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |Syncope
| align="left" style="background:#F5F5F5;" + |Khorana risk score for venous thromboembolism in cancer patients
| align="left" style="background:#F5F5F5;" + |EGSYS (Evaluation of Guidelines in SYncope Study) Score for Syncope
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts likelihood that syncope is from cardiac cause
|-
|-
! align="center" style="background:#DCDCDC;" + |VTE
! align="center" style="background:#DCDCDC;" + |VTE
| align="left" style="background:#F5F5F5;" + |Michigan risk score for picc-related thrombosis
| align="left" style="background:#F5F5F5;" + |Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts need for VTE prophylaxis in admitted patients
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Geneva score for PE, original
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Determines the pre-test probability of PE based on a patient's risk factors and clinical findings
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |ACTION ICU score for intensive care in NSTEMI
| align="left" style="background:#F5F5F5;" + |Geneva score for PE, revised
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Objectifies risk of PE, like Wells’ score
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |ADAPT protocol for cardiac event risk
| align="left" style="background:#F5F5F5;" + |Geneva score for PE, simplified
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Determines the pre-test probability of PE based on a patient's risk factors and clinical findings
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Cardiac arrest/Survival
| align="left" style="background:#F5F5F5;" + |Aortic dissection detection risk score (ADD-RS)
| align="left" style="background:#F5F5F5;" + |GO-FAR (Good Outcome Following Attempted Resuscitation) Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts survival to discharge with good outcome after in-hospital cardiac arrest
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |Canadian Cardiovascular Society (CCS) angina grade
| align="left" style="background:#F5F5F5;" + |Grace Risk Score for All-Cause Mortality From Discharge to 6 Months
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Assesses the risk of 6-month mortality among patients with acute coronary syndrome
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |CRUSADE score for post-mi bleeding risk
| align="left" style="background:#F5F5F5;" + |Grace Risk Score for In-Hospital Mortality
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Assesses the risk of in-hospital mortality among patients with acute coronary syndrome
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |DVT
| align="left" style="background:#F5F5F5;" + |Dual Antiplatelet Therapy (DAPT) score
| align="left" style="background:#F5F5F5;" + |HAMILTON score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Assesses the pretest probability of DVT among ambulatory outpatients
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Bleeding
| align="left" style="background:#F5F5F5;" + |Duke treadmill score
| align="left" style="background:#F5F5F5;" + |HAS-BLED Score for Major Bleeding Risk
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates risk of major bleeding for patients on anticoagulation to assess risk-benefit in atrial fibrillation care
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |Emergency Department Assessment of Chest Pain Score (EDACS)
| align="left" style="background:#F5F5F5;" + |HEART Pathway for Early Discharge in Acute Chest Pain
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Identifies emergency department patients with acute chest pain for early discharge
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |Framingham Risk Score for hard coronary heart disease
| align="left" style="background:#F5F5F5;" + |HEART Score for Major Cardiac Events
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 6-week risk of major adverse cardiac event
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Arrythmia/Bleeding
| align="left" style="background:#F5F5F5;" + |GRACE ACS risk and mortality calculator
| align="left" style="background:#F5F5F5;" + |HEMORR₂HAGES Score for Major Bleeding Risk
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Quantifies risk of hemorrhage in elderly patients with AFib
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |Killip classification for heart failure
| align="left" style="background:#F5F5F5;" + |Hestia Criteria for Outpatient Pulmonary Embolism Treatment
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Identifies low-risk PE patients safe for outpatient treatment
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Bleeding
| align="left" style="background:#F5F5F5;" + |LDL calculated
| align="left" style="background:#F5F5F5;" + |IMPROVE bleeding risk score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the probability of major or clinically important in-hospital bleeding from the time of hospital admission up to 14 days following admission
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |VTE
| align="left" style="background:#F5F5F5;" + |Marburg Heart Score (MHS)
| align="left" style="background:#F5F5F5;" + |IMPROVE VTE risk score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the probability of clinically evident acute venous thromboembolism from the time of hospital admission to discharge
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |VTE
| align="left" style="background:#F5F5F5;" + |Modified Early Warning Score (MEWS) for clinical deterioration
| align="left" style="background:#F5F5F5;" + |IMPROVEDD VTE risk score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the probability of venous thromboembolism from the time of hospital admission up to 77 days
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Infective endocarditis/Mortality
| align="left" style="background:#F5F5F5;" + |National Early Warning Score (NEWS)
| align="left" style="background:#F5F5F5;" + |Infective Endocarditis (IE) Mortality Risk Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts mortality at 6 months in patients with infective endocarditis
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |San Francisco syncope rule
| align="left" style="background:#F5F5F5;" + |Marburg Heart Score (MHS)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Rules out coronary artery disease in primary care patients with chest pain
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Nephropathy
| align="left" style="background:#F5F5F5;" + |Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid
| align="left" style="background:#F5F5F5;" + |Mehran Score for Post-PCI Contrast Nephropathy
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts risk of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI)
|-
|-
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
! align="center" style="background:#DCDCDC;" + |Syncope/Mortality
| align="left" style="background:#F5F5F5;" + |Vancouver chest pain rule
| align="left" style="background:#F5F5F5;" + |OESIL Score for Syncope
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates 12-month all-cause mortality in patients presenting with syncope
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Heart failure
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Ottawa Heart Failure Risk Scale (OHFRS)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Identifies ED patients with heart failure at high risk for serious adverse events
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |VTE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Padua Prediction Score for Risk of VTE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Determines anticoagulation need in hospitalized patients by risk of VTE
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |PESI (Pulmonary Embolism Severity Index)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 30-day outcome of patients with pulmonary embolism using 11 clinical criteria
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |PESI (Pulmonary Embolism Severity Index), simplified
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 30-day outcome of patients with PE, with fewer criteria than the original PESI
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE/Bleeding
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |RIETE Score for Risk of Hemorrhage in Pulmonary Embolism Treatment
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Determine the risk of major bleeding during anticoagulant therapy
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Stroke/Mortality
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |SOAR Score for Stroke, modified
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts short-term mortality in acute ischemic stroke
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |TIMI Risk Score for STEMI
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates mortality in patients with STEMI
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |TIMI Risk Score for UA/NSTEMI
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates mortality for patients with unstable angina and non-ST elevation MI
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |DVT
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Wells score for DVT, modified
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the pre-test probability of DVT
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |DVT
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Wells score for DVT, original
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Calculates Wells' Score for risk of DVT
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Wells score for Pulmonary Embolism
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Objectifies risk of pulmonary embolism
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Wells score for pulmonary embolism, modified
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the pre-test probability of PE
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Wells score for pulmonary embolism, simplified
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the pre-test probability of PE
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Anesthesia
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Cardiac Anesthesia Risk Evaluation Score (CARE)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts mortality and morbidity after cardiac surgery
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Duke Activity Status Index (DASI)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates functional capacity
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Ehlers-Danlos Syndrome
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Ehlers-Danlos Syndrome IV (vascular type) Diagnostic Criteria
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Diagnoses Ehlers-Danlos Syndrome IV (vascular type)
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Emergency Department Assessment of Chest Pain Score (EDACS)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Identifies chest pain patients with low risk of major adverse cardiac event
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |EuroSCORE for Cardiac Surgery Risk Assessment
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the mortality among cardiac surgical adult patients
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Framingham 10 Year Coronary Risk Prediction by LDL (1998 paper)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 10-year risk of coronary heart disease
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Framingham 10 Year Coronary Risk Prediction by Total Cholesterol (1998 paper)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 10-year risk of coronary heart disease
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |MACE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Framingham 10 Year Risk of General Cardiovascular Disease (2008 paper)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 10-year risk of heart disease
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Heart failure
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Framingham Heart Failure Diagnostic Criteria
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Diagnoses heart failure based on major and minor criteria
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Heart failure
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |GWTG-Heart Failure Risk Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts in-hospital all-cause heart failure mortality
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Takayasu arteritis
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Indian Takayasu Clinical Activity Score (ITAS2010)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Differentiates between active and inactive disease in Takayasu arteritis (TA)
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Bleeding
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Intracranial Bleeding Risk from Thrombolytic Therapy of MI
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates the risk of intracranial hemorrhage associated with thrombolytic therapy among MI patients
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Acute Rheumatic Fever
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Jones Criteria for Acute Rheumatic Fever Diagnosis
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Diagnoses acute rheumatic fever based on major and minor criteria
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Kawasaki Disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Kawasaki Disease Diagnostic Criteria
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Diagnoses Kawasaki Disease
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Heart failure
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Killip Classification for Heart Failure
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Quantifies severity of heart failure in ACS and predicts 30-day mortality
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Readmission/Mortality
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |LACE Index for Readmission
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts 30-day readmission or death in patients on medicine and surgery wards
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Heart failure/Mortality
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |MAGGIC Risk  for Heart Failure
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Estimates 1- and 3- year mortality in heart failure
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Metabolic syndrome
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Metabolic Syndrome Criteria (AHA/NHLBI 2005)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Assists to diagnose and manage metabolic syndrome
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Metabolic syndrome
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Metabolic Syndrome Criteria (ATP III)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Diagnoses of metabolic syndrome
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Dyspnea
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |mMRC (Modified Medical Research Council) Dyspnea Scale
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Stratifies severity of dyspnea in respiratory diseases, particularly COPD
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Mortality
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Modified Early Warning Score (MEWS) for Clinical Deterioration
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Determines the degree of illness of a patient
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Chest pain
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Newsom Score for Non-traumatic Chest Pain
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Rules out need for chest x-ray in chest pain patients (non-traumatic)
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Pacer
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Pacer Need After Heart Valve Surgery
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts the need for permanent pacing after cardiac valve surgery
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Pediatric Early Warning Score (PEWS)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Identifies pediatric patients at risk for clinical deterioration
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |PE
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |PERC Rule for Pulmonary Embolism
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Rules out PE if no criteria are present and pre-test probability is ≤15%
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Operation
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |PTCA Mortality Prediction
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts the risk of major in-hospital complications following percutaneous coronary interventions
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Pulmonary arterial hypertension
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |REVEAL Registry Risk Score for Pulmonary Arterial Hypertension (PAH)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts survival in patients with pulmonary arterial hypertension
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Stroke
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Risk of Paradoxical Embolism (RoPE) Score
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Identifies stroke-related PFO in patients with cryptogenic stroke
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Imaging
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Romhilt-Estes Criteria for Left Ventricular Hypertrophy
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Syncope
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |San Francisco Syncope Rule
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Defines high-risk criteria for patients with syncope
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Sgarbossa's Criteria for MI in Left Bundle Branch Block
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Criteria to diagnose acute MI in patients with prior LBBB
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Imaging
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Stress Test Outcome Risk Factors
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts outcome in a community-based population undergoing stress testing
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Stroke
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |tPA Contraindications for Ischemic Stroke
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Provides inclusion/exclusion criteria when deciding to use tPA on a patient with acute ischemic stroke
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Troponin-only Manchester Acute Coronary Syndromes (T-MACS) Decision Aid
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Rules out acute coronary syndrome
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Unstable Angina and Tirofiban Benefit Prediction
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Unstable Angina Risk Stratification (Piombo)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Predicts stratify risk in unstable angina
|-
|-
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |Coronary artery disease
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Unstable Angina Risk Stratification (Solomon)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |Identifies patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
|}
|}

Revision as of 02:44, 31 January 2019

Calculator project
Introduction
Guide
Template
Topics
Validated Scores
Alphabetic Order

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

CARDIOLOGY

Topic Calculators Purpose
Coronary artery disease ACTION ICU Score for Intensive Care in NSTEMI Predicts risk of NSTEMI complications requiring ICU care
MACE ADAPT Protocol for Cardiac Event Risk Assesses chest pain patients at 2 hours for risk of cardiac event
DVT AMUSE score Evaluates the need to proceed with ultrasonography among patients with suspected DVT
Anticoagulation ATRIA Bleeding Risk Score Determines bleeding risk for patients on warfarin
Arrythmia ATRIA Stroke Risk Score Determines stroke risk in patients with atrial fibrillation
Arrythmia/Stroke Atrial Fibrillation Five Year Risk of Stroke (Framingham Heart Study) Predicts 5-year risk of stroke in patients with atrial fibrillation
Arrythmia/Stroke Atrial Fibrillation Five Year Risk of Stroke or Death (Framingham Heart Study) Predicts 5-year risk of stroke or death in patients with atrial fibrillation
Alcoholism CAGE Questions for Alcohol Use Screens for excessive drinking and alcoholism
Syncope Canadian Syncope Risk Score Predicts 30-day serious adverse events in patients presenting with syncope
VTE Caprini score Stratifies risk of VTE in surgical patients
MACE Cardiac Risk Index for AAA Surgery (Lee) Calculates the approximate risk of cardiac complication after AAA surgery
MACE Cardiac Risk Index for Abdominal Surgery (Lee) Calculates the approximate risk of cardiac complication after abdominal surgery
MACE Cardiac Risk Index for Pre-Operative Risk, revised Estimates risk of cardiac complications after noncardiac surgery
MACE Cardiovascular Risk Assessment (10-year, PROCAM Score, Munster Heart Study) Predicts 10-year cardiovascular risk based on risk factors like history of MI, diabetes or high cholesterol
Cardiac arrest CART (Cardiac Arrest Risk Triage) Score Predicts risk of in-hospital cardiac arrest
Arrythmia/Stroke CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk Calculates stroke risk for patients with atrial fibrillation, possibly better than the CHADS₂ Score
Arrythmia/Stroke CHADS₂ Score for Atrial Fibrillation Stroke Risk Estimates stroke risk in patients with atrial fibrillation
Survival Charlson Comorbidity Index (CCI) Predicts 10-year survival in patients with multiple comorbidities
Stroke Cincinnati Prehospital Stroke Severity Scale (CP-SSS) Predicts large vessel occlusion (LVO) and severe stroke in patients with stroke symptoms
Coronary artery disease/Bleeding CRUSADE Score for Post-MI Bleeding Risk Stratifies bleeding risk after NSTEMI
VTE DASH Prediction Score for Recurrent VTE Predicts likelihood of recurrence of first VTE
Coronary artery disease Dual Antiplatelet Therapy (DAPT) Score Predicts which patients will benefit from prolonged DAPT after coronary stent placement
Syncope EGSYS (Evaluation of Guidelines in SYncope Study) Score for Syncope Predicts likelihood that syncope is from cardiac cause
VTE Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis Predicts need for VTE prophylaxis in admitted patients
PE Geneva score for PE, original Determines the pre-test probability of PE based on a patient's risk factors and clinical findings
PE Geneva score for PE, revised Objectifies risk of PE, like Wells’ score
PE Geneva score for PE, simplified Determines the pre-test probability of PE based on a patient's risk factors and clinical findings
Cardiac arrest/Survival GO-FAR (Good Outcome Following Attempted Resuscitation) Score Predicts survival to discharge with good outcome after in-hospital cardiac arrest
Coronary artery disease Grace Risk Score for All-Cause Mortality From Discharge to 6 Months Assesses the risk of 6-month mortality among patients with acute coronary syndrome
Coronary artery disease Grace Risk Score for In-Hospital Mortality Assesses the risk of in-hospital mortality among patients with acute coronary syndrome
DVT HAMILTON score Assesses the pretest probability of DVT among ambulatory outpatients
Bleeding HAS-BLED Score for Major Bleeding Risk Estimates risk of major bleeding for patients on anticoagulation to assess risk-benefit in atrial fibrillation care
Coronary artery disease HEART Pathway for Early Discharge in Acute Chest Pain Identifies emergency department patients with acute chest pain for early discharge
MACE HEART Score for Major Cardiac Events Predicts 6-week risk of major adverse cardiac event
Arrythmia/Bleeding HEMORR₂HAGES Score for Major Bleeding Risk Quantifies risk of hemorrhage in elderly patients with AFib
PE Hestia Criteria for Outpatient Pulmonary Embolism Treatment Identifies low-risk PE patients safe for outpatient treatment
Bleeding IMPROVE bleeding risk score Estimates the probability of major or clinically important in-hospital bleeding from the time of hospital admission up to 14 days following admission
VTE IMPROVE VTE risk score Estimates the probability of clinically evident acute venous thromboembolism from the time of hospital admission to discharge
VTE IMPROVEDD VTE risk score Estimates the probability of venous thromboembolism from the time of hospital admission up to 77 days
Infective endocarditis/Mortality Infective Endocarditis (IE) Mortality Risk Score Predicts mortality at 6 months in patients with infective endocarditis
Coronary artery disease Marburg Heart Score (MHS) Rules out coronary artery disease in primary care patients with chest pain
Nephropathy Mehran Score for Post-PCI Contrast Nephropathy Predicts risk of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI)
Syncope/Mortality OESIL Score for Syncope Estimates 12-month all-cause mortality in patients presenting with syncope
Heart failure Ottawa Heart Failure Risk Scale (OHFRS) Identifies ED patients with heart failure at high risk for serious adverse events
VTE Padua Prediction Score for Risk of VTE Determines anticoagulation need in hospitalized patients by risk of VTE
PE PESI (Pulmonary Embolism Severity Index) Predicts 30-day outcome of patients with pulmonary embolism using 11 clinical criteria
PE PESI (Pulmonary Embolism Severity Index), simplified Predicts 30-day outcome of patients with PE, with fewer criteria than the original PESI
PE/Bleeding RIETE Score for Risk of Hemorrhage in Pulmonary Embolism Treatment Determine the risk of major bleeding during anticoagulant therapy
Stroke/Mortality SOAR Score for Stroke, modified Predicts short-term mortality in acute ischemic stroke
Coronary artery disease TIMI Risk Score for STEMI Estimates mortality in patients with STEMI
Coronary artery disease TIMI Risk Score for UA/NSTEMI Estimates mortality for patients with unstable angina and non-ST elevation MI
DVT Wells score for DVT, modified Estimates the pre-test probability of DVT
DVT Wells score for DVT, original Calculates Wells' Score for risk of DVT
PE Wells score for Pulmonary Embolism Objectifies risk of pulmonary embolism
PE Wells score for pulmonary embolism, modified Estimates the pre-test probability of PE
PE Wells score for pulmonary embolism, simplified Estimates the pre-test probability of PE
Anesthesia Cardiac Anesthesia Risk Evaluation Score (CARE) Predicts mortality and morbidity after cardiac surgery
Duke Activity Status Index (DASI) Estimates functional capacity
Ehlers-Danlos Syndrome Ehlers-Danlos Syndrome IV (vascular type) Diagnostic Criteria Diagnoses Ehlers-Danlos Syndrome IV (vascular type)
Coronary artery disease Emergency Department Assessment of Chest Pain Score (EDACS) Identifies chest pain patients with low risk of major adverse cardiac event
MACE EuroSCORE for Cardiac Surgery Risk Assessment Estimates the mortality among cardiac surgical adult patients
MACE Framingham 10 Year Coronary Risk Prediction by LDL (1998 paper) Predicts 10-year risk of coronary heart disease
MACE Framingham 10 Year Coronary Risk Prediction by Total Cholesterol (1998 paper) Predicts 10-year risk of coronary heart disease
MACE Framingham 10 Year Risk of General Cardiovascular Disease (2008 paper) Predicts 10-year risk of heart disease
Heart failure Framingham Heart Failure Diagnostic Criteria Diagnoses heart failure based on major and minor criteria
Heart failure GWTG-Heart Failure Risk Score Predicts in-hospital all-cause heart failure mortality
Takayasu arteritis Indian Takayasu Clinical Activity Score (ITAS2010) Differentiates between active and inactive disease in Takayasu arteritis (TA)
Bleeding Intracranial Bleeding Risk from Thrombolytic Therapy of MI Estimates the risk of intracranial hemorrhage associated with thrombolytic therapy among MI patients
Acute Rheumatic Fever Jones Criteria for Acute Rheumatic Fever Diagnosis Diagnoses acute rheumatic fever based on major and minor criteria
Kawasaki Disease Kawasaki Disease Diagnostic Criteria Diagnoses Kawasaki Disease
Heart failure Killip Classification for Heart Failure Quantifies severity of heart failure in ACS and predicts 30-day mortality
Readmission/Mortality LACE Index for Readmission Predicts 30-day readmission or death in patients on medicine and surgery wards
Heart failure/Mortality MAGGIC Risk for Heart Failure Estimates 1- and 3- year mortality in heart failure
Metabolic syndrome Metabolic Syndrome Criteria (AHA/NHLBI 2005) Assists to diagnose and manage metabolic syndrome
Metabolic syndrome Metabolic Syndrome Criteria (ATP III) Diagnoses of metabolic syndrome
Dyspnea mMRC (Modified Medical Research Council) Dyspnea Scale Stratifies severity of dyspnea in respiratory diseases, particularly COPD
Mortality Modified Early Warning Score (MEWS) for Clinical Deterioration Determines the degree of illness of a patient
Chest pain Newsom Score for Non-traumatic Chest Pain Rules out need for chest x-ray in chest pain patients (non-traumatic)
Pacer Pacer Need After Heart Valve Surgery Predicts the need for permanent pacing after cardiac valve surgery
Pediatric Early Warning Score (PEWS) Identifies pediatric patients at risk for clinical deterioration
PE PERC Rule for Pulmonary Embolism Rules out PE if no criteria are present and pre-test probability is ≤15%
Operation PTCA Mortality Prediction Predicts the risk of major in-hospital complications following percutaneous coronary interventions
Pulmonary arterial hypertension REVEAL Registry Risk Score for Pulmonary Arterial Hypertension (PAH) Predicts survival in patients with pulmonary arterial hypertension
Stroke Risk of Paradoxical Embolism (RoPE) Score Identifies stroke-related PFO in patients with cryptogenic stroke
Imaging Romhilt-Estes Criteria for Left Ventricular Hypertrophy Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy
Syncope San Francisco Syncope Rule Defines high-risk criteria for patients with syncope
Coronary artery disease Sgarbossa's Criteria for MI in Left Bundle Branch Block Criteria to diagnose acute MI in patients with prior LBBB
Imaging Stress Test Outcome Risk Factors Predicts outcome in a community-based population undergoing stress testing
Stroke tPA Contraindications for Ischemic Stroke Provides inclusion/exclusion criteria when deciding to use tPA on a patient with acute ischemic stroke
Coronary artery disease Troponin-only Manchester Acute Coronary Syndromes (T-MACS) Decision Aid Rules out acute coronary syndrome
Coronary artery disease Unstable Angina and Tirofiban Benefit Prediction Predicts adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris
Coronary artery disease Unstable Angina Risk Stratification (Piombo) Predicts stratify risk in unstable angina
Coronary artery disease Unstable Angina Risk Stratification (Solomon) Identifies patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy

CRITICAL CARE

Topic Calculators Purpose
Stroke Cincinnati stroke scale
SIRS, Sepsis, and Septic Shock Criteria
qSOFA (Quick SOFA) Score for Sepsis

GASTROENTEROLOGY

Topic Calculators Purpose
Liver disease MELD Score
Liver disease Child-Pugh score for cirrhosis mortality
Pancreatitis Ranson criteria
Pericarditis Tygerberg score

HEMATOLOGY/ONCOLOGY

Topic Calculators Purpose
Myelofibrosis DIPSS Plus Score
CBC Absolute Neutrophil Count (ANC)

INFECTIOUS DISEASE

Topic Calculators Purpose
ENT Centor Score (Modified/McIsaac) for Strep Pharyngitis

NEPHROLOGY

Topic Calculators Purpose
Creatinine clearance
Sodium correction for hyperglycemia
Fractional Excretion of Sodium (FENa)
Calcium correction for hypoalbuminemia
Fluid Maintenance fluids calculations

NEUROLOGY

Topic Calculators Purpose
Level of consciousness Glasgow coma scale
Level of consciousness Pediatric Glasgow Coma Scale
Stroke Cincinnati stroke scale
Stroke NIH Stroke Scale/Score (NIHSS)

PEDIATRICS

Topic Calculators Purpose
Level of consciousness Pediatric Glasgow Coma Scale
Neonatology Apgar score

PULMONOLOGY

Topic Calculators Purpose
Pneumonia CURB-65
Pneumonia Pneumonia severity index

ORTHOPEDICS

Topic Calculators Purpose
Open Fractures Mangled Extremity Score Clinician completed the score to determine which mangled limbs will eventually come to amputation.
Open Fractures Ganga Hospital Open Injury Score (GHOIS) Clinician completed the score to help them in decision making regarding salvage in IIIB injuries.
Knee (Anterior Cruciate Ligament) Modified Cincinnati Rating system
Knee (Anterior Cruciate Ligament) Tegner Lysholm Knee Scoring Scale
Knee (Anterior Cruciate Ligament) KOOS (Knee Injury & Osteoarthritis Outcome)
Knee (Osteoarthritis) Oxford Knee Score
Knee (Osteoarthritis) KOOS (Knee Injury & Osteoarthritis Outcome)
Knee (Osteoarthritis) WOMAC Score
Knee (Osteoarthritis) IKDC
Knee (Osteoarthritis) Knee Society Score (KSS)
Foot/Ankle American Foot & Ankle Score
Foot/Ankle Foot & Ankle Disability Index
Wrist MAYO Wrist Score
Wrist DASH (Disabilities of arm, shoulder & hand) Score
Wrist Quick-DASH Score
Hand Michigan Hand Outcomes Questionnaire
Hand DASH (Disabilities of arm, shoulder & hand) Score
Hand Quick-DASH Score
Lumbar Spine Oswestry Low Back Pain Score
Lumbar Spine Modified Oswestry Low Back Pain Score
Lumbar Spine Back Pain Index
Cervical Spine Vernon & Mior Cervical Spine Score
Hip Harris Hip Score
Hip Oxford Hip Score
Hip HOOS (Hip disability and Osteoarthritis Outcome)
Hip WOMAC Score
Shoulder Constant Shoulder Score
Shoulder UCLA Shoulder rating scale
Shoulder Oxford Shoulder Score
Shoulder American Shoulder And Elbow Surgeons (ASES) Society Score
Shoulder DASH (Disabilities of arm, shoulder & hand) Score
Shoulder Quick-DASH Score
Shoulder (Instability) Rowe Score for Instability
Shoulder (Instability) Oxford Shoulder Instability Score
Shoulder (Instability) WOSI (Western Ontario Shoulder Instability Index)
Elbow MAYO Elbow Score
Elbow Oxford Elbow Score
Elbow DASH (Disabilities of arm, shoulder & hand) Score
Elbow Quick-DASH Score
VAS VAS Score
Psychological DRAM (Distress and Risk Assessment Method)